EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Hematopoietic Cell Transplant Access and Patient Diversity

Rachel Cusatis, Jianqun Kou, Caitrin Bupp, Deborah Mattila, Ramzi Abboud, Sally Arai, Javier Bolaños Meade, George Carrum, Bhagirathbhai Dholaria, Fatema Fareh, Mehdi Hamadani, William J Hogan und 18 weitere

JAMA Network Open · 05.05.2026 · 9 (5) · e2610839

DOI: 10.1001/jamanetworkopen.2026.10839 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Network Open, online erschienen am 05.05.2026. Verfasst von Rachel Cusatis und 29 weiteren Autor:innen. Beteiligte Einrichtung: CIBMTR, Medical College of Wisconsin, Milwaukee. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Health Services Accessibility. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Allogeneic hematopoietic cell transplant (HCT) is curative for hematologic cancers, yet access remains inequitable for racially and ethnically underrepresented and socioeconomically disadvantaged populations, making the goal of having a suitable donor for every patient who needs a transplant challenging. The ACCESS trial broadened access by enrolling patients without matched donors, who instead received an HCT from a mismatched unrelated donor.

Objective

To compare baseline characteristics of ACCESS trial participants with participants enrolled in a similar clinical trial and a patient-reported outcome (PRO) protocol cohort. Design, Setting, and Participants This cross-sectional study included adult participants (aged ≥18 years) from 3 cohorts—the ACCESS trial (2021-2024), BMT CTN 1703 trial (2019-2021), and Center for International Blood and Marrow Transplant Research (CIBMTR) PRO Protocol observational study (2020-2025)—who completed a baseline PRO survey. The ACCESS and PRO Protocol cohorts were stratified by conditioning intensity (myeloablative [MAC] vs reduced-intensity and nonmyeloablative [RIC/NMA]); all BMT CTN 1703 participants received RIC/NMA. Exposure Hematopoietic cell transplant. Main Outcomes and Measures Racial and ethnic diversity, insurance type, education, and income were compared among cohorts using counts and percentages, and socioeconomic and structural disadvantage were measured using the Social Vulnerability Index and Comprehensive Score for Financial Toxicity–Functional Assessment of Chronic Illness Therapy.

Results

Baseline surveys were completed by 208 participants in the ACCESS trial (median [range] age at transplant, 62.3 [20.4-78.9] years; 108 male [51.9%]), 122 participants in the PRO Protocol study (median [range] age at transplant, 63.9 [21.1-78.0] years; 67 male [54.9%]), and 342 participants in the BMT CTN 1703 trial (median [range] age at transplant, 66.9 [20.7-78.6] years; 218 male [63.7%]). Participants in ACCESS were more racially and ethnically diverse, with 15 (7.2%), 25 (12.1%), 46 (22.2%), 110 (53.1%), and 11 (5.3%) of Asian, Black or African American, Hispanic or Latino, White, and other race and ethnicity, respectively, compared with 4 (3.3%), 2 (1.6%), 8 (6.6%) 104 (85.2%), and 4 (3.3%), respectively, in the PRO Protocol and 10 (3.0%), 0, 16 (4.8%), 302 (91.0%), and 4 (1.2%), respectively, in the BMT CTN 1703 trial. Participants in ACCESS were more likely to have Medicaid (36 [18.1%]) vs PRO Protocol (8 [6.7%]) and BMT CTN 1703 (14 [4.7%]) participants and reported lower education (some college or an associate’s degree: 103 [49.5%] vs 73 [59.8%] in the PRO Protocol; postcollege education: 34 [17.3%] vs 35 [29.2%] in the PRO Protocol) and household income (<$40 000 annually: 25 [24.0%] vs 8 [11.6%] in the PRO Protocol and 7 [38.9%] in the BMT CTN 1703 trial). Median Social Vulnerability Index scores were highest among participants in the ACCESS MAC group (median [range], 0.72 [0.01-0.97] vs 0.61 [0.16-0.78] in the PRO Protocol MAC group), and 16 participants [27.6%] in the ACCESS MAC group reported moderate to severe financial toxicity. The ACCESS participants lived closer to transplant centers, especially in the RIC/NMA group (median [IQR], 27 [13-75] miles vs 47 [16-96] miles for BMT CTN 1703 participants and 49 [21-104] miles for PRO Protocol participants). Conclusions and Relevance This cross-sectional study of clinical trial participants and a clinical cohort found that the ACCESS trial enrolled a more racially and ethnically diverse and socioeconomically disadvantaged population. Trial designs that broaden eligibility could expand access to HCT, highlighting the need for systemic interventions to ensure equity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHealth Services AccessibilityHumansMaleCross-Sectional StudiesFemaleMiddle AgedAdultHealthcare DisparitiesAgedEthnicityDiversity, Equity, InclusionSocioeconomic Disparities in Health

Autor:innen und Institutionen

  • CIBMTR, Medical College of Wisconsin, Milwaukee.
  • Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee.
  • CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, Minnesota.
  • Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Stanford Health Care, Palo Alto, California.
  • Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Förderung

  • NCI NIH HHS

Zitieren

APA

Cusatis, R., Kou, J., Bupp, C., Mattila, D., Abboud, R., Arai, S., Bolaños Meade, J., Carrum, G., Dholaria, B., Fareh, F., Hamadani, M., Hogan, W. J., Jamieson, K., Jimenez Jimenez, A. M., Khimani, F., Kelkar, A. H., Kosuri, S., Larkin, K. T., Al Malki, M. M., …, & Shaw, B. E. (2026). Hematopoietic Cell Transplant Access and Patient Diversity. JAMA Network Open, 9(5), e2610839. https://doi.org/10.1001/jamanetworkopen.2026.10839

Vancouver

Cusatis R, Kou J, Bupp C, Mattila D, Abboud R, Arai S, et al. Hematopoietic Cell Transplant Access and Patient Diversity. JAMA Network Open. 2026;9(5):e2610839. doi:10.1001/jamanetworkopen.2026.10839

BibTeX
@article{Cusatis2026,
  author = {Cusatis, Rachel and Kou, Jianqun and Bupp, Caitrin and Mattila, Deborah and Abboud, Ramzi and Arai, Sally and Bolaños Meade, Javier and Carrum, George and Dholaria, Bhagirathbhai and Fareh, Fatema and Hamadani, Mehdi and Hogan, William J and Jamieson, Katarzyna and Jimenez Jimenez, Antonio M and Khimani, Farhad and Kelkar, Amar H and Kosuri, Satyajit and Larkin, Karilyn T and Al Malki, Monzr M and McCurdy, Shannon R and Milner, Jordan and Modi, Dipenkumar and Reshef, Ran and Shaffer, Brian C and Shanmugasundaram, Krithika and Rao, Uttam and Auletta, Jeffrey J and Devine, Steven M and Logan, Brent R and Shaw, Bronwen E},
  title = {Hematopoietic Cell Transplant Access and Patient Diversity},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {5},
  pages = {e2610839},
  doi = {10.1001/jamanetworkopen.2026.10839}
}
Kostenlos starten →